337 related articles for article (PubMed ID: 18793607)
1. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Anal Biochem; 2008 Dec; 383(2):205-9. PubMed ID: 18793607
[TBL] [Abstract][Full Text] [Related]
2. Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3.
Reindl W; Gräber M; Strebhardt K; Berg T
Anal Biochem; 2009 Dec; 395(2):189-94. PubMed ID: 19716361
[TBL] [Abstract][Full Text] [Related]
3. A fluorescence polarization assay for the discovery of inhibitors of the polo-box domain of polo-like kinase 1.
Reindl W; Strebhardt K; Berg T
Methods Mol Biol; 2012; 795():69-81. PubMed ID: 21960216
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chem Biol; 2008 May; 15(5):459-66. PubMed ID: 18482698
[TBL] [Abstract][Full Text] [Related]
5. Pinning down the polo-box domain.
Lee KS; Idle JR
Chem Biol; 2008 May; 15(5):415-6. PubMed ID: 18482691
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
Johnson EF; Stewart KD; Woods KW; Giranda VL; Luo Y
Biochemistry; 2007 Aug; 46(33):9551-63. PubMed ID: 17655330
[TBL] [Abstract][Full Text] [Related]
8. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
Elling RA; Fucini RV; Romanowski MJ
Acta Crystallogr D Biol Crystallogr; 2008 Sep; 64(Pt 9):909-18. PubMed ID: 18703838
[TBL] [Abstract][Full Text] [Related]
9. Development of a High-Throughput Assay for Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1 Based on Time-Resolved Fluorescence Energy Transfer.
Kim TG; Lee JH; Lee MY; Kim KU; Lee JH; Park CH; Lee BH; Oh KS
Biol Pharm Bull; 2017; 40(9):1454-1462. PubMed ID: 28867728
[TBL] [Abstract][Full Text] [Related]
10. Structure of the catalytic domain of human polo-like kinase 1.
Kothe M; Kohls D; Low S; Coli R; Cheng AC; Jacques SL; Johnson TL; Lewis C; Loh C; Nonomiya J; Sheils AL; Verdries KA; Wynn TA; Kuhn C; Ding YH
Biochemistry; 2007 May; 46(20):5960-71. PubMed ID: 17461553
[TBL] [Abstract][Full Text] [Related]
11. A new class of peptidomimetics targeting the polo-box domain of Polo-like kinase 1.
Ahn M; Han YH; Park JE; Kim S; Lee WC; Lee SJ; Gunasekaran P; Cheong C; Shin SY; Kim HY; Ryu EK; Murugan RN; Kim NH; Bang JK
J Med Chem; 2015 Jan; 58(1):294-304. PubMed ID: 25347203
[TBL] [Abstract][Full Text] [Related]
12. Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides.
Zhao XZ; Hymel D; Burke TR
Bioorg Med Chem; 2017 Oct; 25(19):5041-5049. PubMed ID: 28285924
[TBL] [Abstract][Full Text] [Related]
13. Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain.
Scharow A; Knappe D; Reindl W; Hoffmann R; Berg T
Chembiochem; 2016 Apr; 17(8):759-67. PubMed ID: 26634982
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cellular uptake of a TAT-conjugated peptide inhibitor targeting the polo-box domain of polo-like kinase 1.
Kim SM; Chae MK; Lee C; Yim MS; Bang JK; Ryu EK
Amino Acids; 2014 Nov; 46(11):2595-603. PubMed ID: 25151148
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of the Polo-Box Domain of Polo-Like Kinase 1.
Berg A; Berg T
Chembiochem; 2016 Apr; 17(8):650-6. PubMed ID: 26662918
[TBL] [Abstract][Full Text] [Related]
16. Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization.
García-Alvarez B; de Cárcer G; Ibañez S; Bragado-Nilsson E; Montoya G
Proc Natl Acad Sci U S A; 2007 Feb; 104(9):3107-12. PubMed ID: 17307877
[TBL] [Abstract][Full Text] [Related]
17. Selectivity-determining residues in Plk1.
Kothe M; Kohls D; Low S; Coli R; Rennie GR; Feru F; Kuhn C; Ding YH
Chem Biol Drug Des; 2007 Dec; 70(6):540-6. PubMed ID: 18005335
[TBL] [Abstract][Full Text] [Related]
18. Exploring the binding nature of pyrrolidine pocket-dependent interactions in the polo-box domain of polo-like kinase 1.
Murugan RN; Ahn M; Lee WC; Kim HY; Song JH; Cheong C; Hwang E; Seo JH; Shin SY; Choi SH; Park JE; Bang JK
PLoS One; 2013; 8(11):e80043. PubMed ID: 24223211
[TBL] [Abstract][Full Text] [Related]
19. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1.
Shan HM; Shi Y; Quan J
ChemMedChem; 2015 Jan; 10(1):158-63. PubMed ID: 25196850
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1.
Srinivasrao G; Park JE; Kim S; Ahn M; Cheong C; Nam KY; Gunasekaran P; Hwang E; Kim NH; Shin SY; Lee KS; Ryu E; Bang JK
PLoS One; 2014; 9(9):e107432. PubMed ID: 25211362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
